Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial.
covid-19
disease progression
hcq
mild infection
rct
viral clearance
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
30 Mar 2021
30 Mar 2021
Historique:
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Background Hydroxychloroquine (HCQ) has been considered for the treatment of coronavirus disease 2019 (COVID-19), but data on its efficacy are conflicting. We analyzed the efficacy of HCQ along with standard of care (SOC) treatment, compared with SOC alone, in reducing disease progression in mild COVID-19. Methods A single-center open-label randomized controlled trial was conducted from April 10 to May 31, 2020 at Pak Emirates Military Hospital, Rawalpindi. Five hundred patients of both genders between the ages of 18 and 80 years with mild COVID-19 were enrolled in the study. A total of 349 patients were assigned to the intervention group (standard dose of HCQ plus SOC) and 151 patients were assigned to SOC only. The primary outcome was progression of disease while secondary outcome was polymerase chain reaction (PCR) negativity on days 7 and 14. The results were analyzed on Statistical Package for Social Sciences (SPSS; IBM Corp., Armonk, NY) version 23. A p-value <0.05 was considered significant. Results The median age of the intervention group was 34 ± 11.778 years and control group was 34 ± 9.813 years. Disease progressed in 16 patients, 11 (3.15%) of which were in the intervention group and 5 (3.3%) in the control group (p-value = 0.940). PCR negative cases in intervention and control groups on day 7 were 182 (52.1%) and 54 (35.8%), respectively (p-value = 0.001); and on day 14 were 244 (69.9%) and 110 (72.9%), respectively (p-value = 0.508). Consecutive PCR negativity on days 7 and 14 was observed in 240 (68.8%) patients in the intervention group compared to 106 (70.2%) in the control group (p-value = 0.321). Conclusion The addition of HCQ to SOC in hospitalized mild COVID-19 patients neither stops disease progression nor helps in early and sustained viral clearance.
Identifiants
pubmed: 33936897
doi: 10.7759/cureus.14186
pmc: PMC8083993
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e14186Informations de copyright
Copyright © 2021, Kamran et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670
pubmed: 32196083
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219
pubmed: 32391667
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Ophthalmology. 2017 Mar;124(3):e28-e29
pubmed: 28219513
Clin Infect Dis. 2017 Sep 15;65(6):1026-1032
pubmed: 28520858
Int J Antimicrob Agents. 2020 Mar;55(3):105923
pubmed: 32070753
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
N Engl J Med. 2020 Mar 26;382(13):1278-1280
pubmed: 32069388
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
J Med Chem. 2006 May 4;49(9):2845-9
pubmed: 16640347